Activity of Eribulin in a primary culture of well-differentiated/dedifferentiated adipocytic sarcoma

Alessandro De Vita, Giacomo Miserocchi, Federica Recine, Laura Mercatali, Federica Pieri, Laura Medri, Alberto Bongiovanni, Davide Cavaliere, Chiara Liverani, Chiara Spadazzi, Dino Amadori, Toni Ibrahim

Research output: Contribution to journalArticle

Abstract

Eribulin mesylate is a novel, non-taxane, synthetic microtubule inhibitor showing antitumor activity in a wide range of tumors including soft tissue sarcomas (STS). Eribulin has been recently approved for the treatment of metastatic liposarcoma (LPS) patients previously treated with anthracyclines. This work investigated the mechanism of action of this innovative antitubulin agent in well-differentiated/dedifferentiated LPS (ALT/DDLPS) which represents one of the most common adipocytic sarcoma histotypes. A primary culture of ALT/DDLPS from a 54-year-old patient was established. The anticancer activity of eribulin on the patient-derived primary culture was assessed by MTT and tunel assays. Eribulin efficacy was compared to other drugs approved for the treatment of STS. Cell migration and morphology were examined after exposure to eribulin to better understand the drug mechanism of action. Finally, Western blot analysis of apoptosis and migration proteins was performed. The results showed that eribulin exerts its antiproliferative effect by the arrest of cell motility and induction of apoptosis. Our results highlighted the activity of eribulin in the treatment of ALT/DDLPS patients.

Original languageEnglish
Article number21121662
JournalMolecules
Volume21
Issue number12
DOIs
Publication statusPublished - Dec 1 2016

Fingerprint

eribulin
Sarcoma
Liposarcoma
Cell Movement
Tissue
Apoptosis
Anthracyclines
Microtubules
Pharmaceutical Preparations
Tumors
Assays

Keywords

  • Adipocytic sarcoma
  • Eribulin
  • Microtubule inhibitors
  • Primary culture

ASJC Scopus subject areas

  • Medicine(all)
  • Organic Chemistry

Cite this

Activity of Eribulin in a primary culture of well-differentiated/dedifferentiated adipocytic sarcoma. / De Vita, Alessandro; Miserocchi, Giacomo; Recine, Federica; Mercatali, Laura; Pieri, Federica; Medri, Laura; Bongiovanni, Alberto; Cavaliere, Davide; Liverani, Chiara; Spadazzi, Chiara; Amadori, Dino; Ibrahim, Toni.

In: Molecules, Vol. 21, No. 12, 21121662, 01.12.2016.

Research output: Contribution to journalArticle

@article{0599cdeec4784e56b3dc3ec6fbfd027a,
title = "Activity of Eribulin in a primary culture of well-differentiated/dedifferentiated adipocytic sarcoma",
abstract = "Eribulin mesylate is a novel, non-taxane, synthetic microtubule inhibitor showing antitumor activity in a wide range of tumors including soft tissue sarcomas (STS). Eribulin has been recently approved for the treatment of metastatic liposarcoma (LPS) patients previously treated with anthracyclines. This work investigated the mechanism of action of this innovative antitubulin agent in well-differentiated/dedifferentiated LPS (ALT/DDLPS) which represents one of the most common adipocytic sarcoma histotypes. A primary culture of ALT/DDLPS from a 54-year-old patient was established. The anticancer activity of eribulin on the patient-derived primary culture was assessed by MTT and tunel assays. Eribulin efficacy was compared to other drugs approved for the treatment of STS. Cell migration and morphology were examined after exposure to eribulin to better understand the drug mechanism of action. Finally, Western blot analysis of apoptosis and migration proteins was performed. The results showed that eribulin exerts its antiproliferative effect by the arrest of cell motility and induction of apoptosis. Our results highlighted the activity of eribulin in the treatment of ALT/DDLPS patients.",
keywords = "Adipocytic sarcoma, Eribulin, Microtubule inhibitors, Primary culture",
author = "{De Vita}, Alessandro and Giacomo Miserocchi and Federica Recine and Laura Mercatali and Federica Pieri and Laura Medri and Alberto Bongiovanni and Davide Cavaliere and Chiara Liverani and Chiara Spadazzi and Dino Amadori and Toni Ibrahim",
year = "2016",
month = "12",
day = "1",
doi = "10.3390/molecules21121662",
language = "English",
volume = "21",
journal = "Molecules",
issn = "1420-3049",
publisher = "Multidisciplinary Digital Publishing Institute (MDPI)",
number = "12",

}

TY - JOUR

T1 - Activity of Eribulin in a primary culture of well-differentiated/dedifferentiated adipocytic sarcoma

AU - De Vita, Alessandro

AU - Miserocchi, Giacomo

AU - Recine, Federica

AU - Mercatali, Laura

AU - Pieri, Federica

AU - Medri, Laura

AU - Bongiovanni, Alberto

AU - Cavaliere, Davide

AU - Liverani, Chiara

AU - Spadazzi, Chiara

AU - Amadori, Dino

AU - Ibrahim, Toni

PY - 2016/12/1

Y1 - 2016/12/1

N2 - Eribulin mesylate is a novel, non-taxane, synthetic microtubule inhibitor showing antitumor activity in a wide range of tumors including soft tissue sarcomas (STS). Eribulin has been recently approved for the treatment of metastatic liposarcoma (LPS) patients previously treated with anthracyclines. This work investigated the mechanism of action of this innovative antitubulin agent in well-differentiated/dedifferentiated LPS (ALT/DDLPS) which represents one of the most common adipocytic sarcoma histotypes. A primary culture of ALT/DDLPS from a 54-year-old patient was established. The anticancer activity of eribulin on the patient-derived primary culture was assessed by MTT and tunel assays. Eribulin efficacy was compared to other drugs approved for the treatment of STS. Cell migration and morphology were examined after exposure to eribulin to better understand the drug mechanism of action. Finally, Western blot analysis of apoptosis and migration proteins was performed. The results showed that eribulin exerts its antiproliferative effect by the arrest of cell motility and induction of apoptosis. Our results highlighted the activity of eribulin in the treatment of ALT/DDLPS patients.

AB - Eribulin mesylate is a novel, non-taxane, synthetic microtubule inhibitor showing antitumor activity in a wide range of tumors including soft tissue sarcomas (STS). Eribulin has been recently approved for the treatment of metastatic liposarcoma (LPS) patients previously treated with anthracyclines. This work investigated the mechanism of action of this innovative antitubulin agent in well-differentiated/dedifferentiated LPS (ALT/DDLPS) which represents one of the most common adipocytic sarcoma histotypes. A primary culture of ALT/DDLPS from a 54-year-old patient was established. The anticancer activity of eribulin on the patient-derived primary culture was assessed by MTT and tunel assays. Eribulin efficacy was compared to other drugs approved for the treatment of STS. Cell migration and morphology were examined after exposure to eribulin to better understand the drug mechanism of action. Finally, Western blot analysis of apoptosis and migration proteins was performed. The results showed that eribulin exerts its antiproliferative effect by the arrest of cell motility and induction of apoptosis. Our results highlighted the activity of eribulin in the treatment of ALT/DDLPS patients.

KW - Adipocytic sarcoma

KW - Eribulin

KW - Microtubule inhibitors

KW - Primary culture

UR - http://www.scopus.com/inward/record.url?scp=85003040531&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85003040531&partnerID=8YFLogxK

U2 - 10.3390/molecules21121662

DO - 10.3390/molecules21121662

M3 - Article

AN - SCOPUS:85003040531

VL - 21

JO - Molecules

JF - Molecules

SN - 1420-3049

IS - 12

M1 - 21121662

ER -